<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: IL-33 through its receptor ST2 protects the heart from myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> and <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> in animal models but, paradoxically, increases <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we examined the effect of IL-33 or ST2 administration on autoimmune <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We used pressure-volume relationships and <z:chebi fb="0" ids="6046">isoproterenol</z:chebi> challenge to assess the effect of recombinant (r) IL-33 or rST2 (eg, soluble ST2) administration on the development of autoimmune coxsackievirus B3 <z:mp ids='MP_0001856'>myocarditis</z:mp> and <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> in male BALB/c mice </plain></SENT>
<SENT sid="3" pm="."><plain>The rIL-33 treatment significantly increased <z:hpo ids='HP_0011009'>acute</z:hpo> perimyocarditis (P=0.006) and <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> (P=1.3×10(-5)), impaired cardiac function (maximum ventricular power, P=0.0002), and increased ventricular dilation (end-diastolic volume, P=0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>The rST2 treatment prevented <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> and improved heart function compared with rIL-33 treatment (ejection fraction, P=0.009) </plain></SENT>
<SENT sid="5" pm="."><plain>Neither treatment altered <z:mp ids='MP_0001799'>viral</z:mp> replication </plain></SENT>
<SENT sid="6" pm="."><plain>The rIL-33 treatment increased IL-4, IL-33, IL-1β, and IL-6 levels in the heart during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0001856'>myocarditis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>To determine whether IL-33 altered cardiac function on its own, we administered rIL-33 to undiseased mice and found that rIL-33 induced eosinophilic <z:hpo ids='HP_0001701'>pericarditis</z:hpo> and adversely affected heart function </plain></SENT>
<SENT sid="8" pm="."><plain>We used cytokine knockout mice to determine that this effect was due to IL-33-mediated signaling but not to IL-1β or IL-6 </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: We show for the first time to our knowledge that IL-33 induces eosinophilic <z:hpo ids='HP_0001701'>pericarditis</z:hpo>, whereas soluble ST2 prevents <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> and improves systolic function, and that IL-33 independently adversely affects heart function through the IL-33 receptor </plain></SENT>
</text></document>